image credit: Freepik

AstraZeneca’s Tezspire for severe asthma gets green light in EU

September 21, 2022


Tezspire (tezepelumab) has been cleared for use in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product, based on the results of the PATHFINDER clinical trial programme.

Approval of the first-in-class TSLP inhibitor wasn’t considered a shoo-in, as Tezspire failed one of its two pivotal phase 3 trials, but the Commission and FDA have concluded that the totality of the data – which also included a positive phase 2b study – was enough to show efficacy and safety.

Read More on Pharmaphorum